Abstract:Micha&lstrok Andrzej Okruszko, 1 Maciej Szab&lstrokowski, 1 Mateusz Zarzecki, 1 Magdalena Michnowska-Kobyli&nacuteska, 1 &Lstrokukasz Lisowski, 1 Magda &Lstrokapi&nacuteska, 2 Zofia Stachurska, 2 Anna Szpakowicz, 3 Karol Adam Kami&nacuteski, 2 Joanna Konopi&nacuteska 1 1 Department of Ophthalmology, Medical University of Bialystok, Bia&lstrokystok, 15-089, Poland; 2 Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bia&lstrokystok, Bia&lstrokystok, Poland; 3 Department of Cardiology, Medical University of Bialystok, Bia&lstrokystok, Poland Correspondence: Joanna Konopi&nacuteska, Medical University of Bia&lstrokystok, Kilinskiego 1 STR, Bia&lstrokystok, 15-089, Poland, TelFax + 48857468372, Fax + 48857468372, Email Introduction: Glaucoma is the most common optic neuropathy and the leading cause of irreversible blindness worldwide, which affects 3.54% of the population aged 40– 80 years. Despite numerous published studies, some aspects of glaucoma pathogenesis, serum biomarkers, and their potential link with other diseases remain unclear. Recent articles have proposed that autoimmune, oxidative stress and inflammation may be involved in the pathogenesis of glaucoma. Methods: We investigated the serum expression of 92 inflammatory and neurotrophic factors in glaucoma patients. The study group consisted of 26 glaucoma patients and 192 healthy subjects based on digital fundography. Results: Patients with glaucoma had significantly lower serum expression of IL-2Rβ, TWEAK, CX3CL1, CD6, CD5, LAP TGF-beta1, LIF-R, TRAIL, NT-3, and CCL23 and significantly higher expression of IL-22Rα 1. Conclusion: Our results indicate that patients with glaucoma tend to have lower levels of neuroprotective proteins and higher levels of neuroinflammatory proteins, similar to those observed in psychiatric, neurodegenerative and autoimmune diseases, indicating a potential link between these conditions and glaucoma pathogenesis. Keywords: glaucoma, inflammation, neurodegeneration, proteomics, Olink Glaucoma is the most common optic neuropathy and the leading cause of irreversible blindness worldwide. On average, it affects 3.54% (2.09–5.82%) of the population aged 40–80 years. 1,2 Although there are many advanced treatment options: pharmacological, laser, or surgery, it is estimated that in 2040 glaucoma will distress 111.8 million people. 3 Glaucomatous neuropathy is caused by progressive neurodegeneration of the optic nerve and loss of retinal ganglion cells (RGCs) due to apoptosis, 4,5 which is observed as a characteristic pattern of morphological changes of the optic nerve head (ONH). It is primarily the consequence of a persistent increase in intraocular pressure (IOP); therefore, glaucoma treatment aims to reduce IOP. However, glaucoma can also develop in patients with normal IOP. Furthermore, glaucomatous optic neuropathy in some patients is known to progress despite implementing medications or surgical treatment. This suggests that some undefined underlying molecular mechanisms lead to glaucoma onset and progression, which is why the search for new therapeutic approaches is continually underway. Therefore, it is crucial to find biomarkers of glaucoma that would enable timely diagnosis and expand the understanding of disease pathogenesis. Recent articles have proposed that autoimmune, oxidative stress and inflammation may be involved in the pathogenesis of glaucoma. 6–8 Some studies have found elevated levels of growth factors or cytokines in aqueous humor and serum, suggesting that inflammation involved in their pathophysiology could thus serve as a biomarker for the pathogenesis, development, or severe course of glaucoma. 9–11 Khalef et al 9 reported increased levels of IL-6, IL-8, transforming growth factor β1, tumour necrosis growth factor α and serum amyloid A. Vidal-Villegas et al 6 found increased levels of IL-12, IL-13, and monocyte chemoattractant protein-1 (monocyte chemotactic and activating factor) in aqueous humor glaucomatous patients. Neuroprotection is a therapeutic approach to preserve neural condition and utility. 5 This area is attracting growing attention in glaucoma as it refers to non-IOP-related actions that enable one to prevent or postpone the apoptosis of RGCs. This may be achieved with neurotrophic factors, which regulate the survival, migration, differentiation, proliferation, and maintenance of several classes of neurons. Few studies indicate a possible connection between brain-derived neurotrophic factor, ne -Abstract Truncated-

Inflammation and Neurodegeneration in Glaucoma: Isolated Eye Disease or a Part of a Systemic Disorder? - Serum Proteomic Analysis